Douglas Sborov is an Oncology physician affiliated with University of Utah. OpenAlex indexes 476 publications with 6,209 citations (h-index 36); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1950 Circle Of Hope Dr
Salt Lake City, UT 841125500
Telephone
801-213-3800Provider last certified this registry record 17 Nov 2021.
Clinical trials
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
Sponsor: National Cancer Institute (NCI)
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Sponsor: University of Utah
- Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$127,925openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202515 payments$13,163openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20256 payments$11,930openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.3%Thalidomide Analog29.8%Revlimid71%Pomalyst26%Lenalidomide3%Part D<11 patientsNuclear Export Inhibitor1.5%Xpovio100%Part D<11 patientsDermatology
27.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.4%Acyclovir100%Part D≥80 patientsMetabolism & gastrointestinal
13.2%Proton pump inhibitor5.7%Omeprazole100%Part D≥23 patientsH2 blocker2.9%Famotidine100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”